The Latest Cardiac and Vascular News
– First fiscal quarter revenues of $5.315 billion grew 25.8% on a reported basis. On a currency-neutral basis, revenues increased 24.3%. – BD’s COVID-19 testing sales of $867 million contributed 20.5 percentage points to revenue growth on a reported basis. This includes BD Veritor™ Plus System revenues of $688 million. […]
Company welcomes Dr. Evan Loh, Ms. Leslie Williams and Dr. Rob Scott, seasoned executives with deep cardiovascular development and commercial experience WARRINGTON, Pa., Feb. 4, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today […]
Expands portfolio across Health, Wellness and User Identification for deployment in consumer and medical technology sectors BELFAST, Northern Ireland–(BUSINESS WIRE)–B-Secur, a leader in EKG/ECG technology, today announced that it has received U.S. Food and Drug Administration (FDA) 510(K) clearance of its HeartKey® software library1. B-Secur’s HeartKey® is a suite of powerful […]
STOCKHOLM, Feb. 4, 2021 /PRNewswire/ — Strong order intake and substantial improvement of the company’s order book as well as operating cash flowFourth quarter (October-December 2020) Order intake amounted to 73.1 (54.7) MSEK. Net sales amounted to 45.9 (60.2) MSEK. Operating income for the period before depreciations (EBITDA) totalled 4.3 (11.8) MSEK. Net […]
GHENT, Belgium, Feb. 04, 2021 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces the granting of key patents for the alfapump DSR (Direct Sodium Removal) programme in the U.S. and European Union. […]
TEL AVIV, Israel, Feb. 04, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (“InspireMD”) (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East and Asia, today announced the pricing […]
Allschwil, Switzerland – February 4, 2021 Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year 2020. Business highlights Positive results in the Phase 3 program of daridorexant, demonstrating improved overall sleep and daytime functioning of patients with insomnia Daridorexant new drug application (NDA) submitted to the […]
Conference Call Scheduled for Today, February 3, 2021, at 3:30 PM CT (4:30 PM ET) Revenues of $64.2 million increased 6% sequentially compared to first quarter Net loss was $0.1 million, or $0.00 per basic and diluted share Management provides fiscal 2021 third quarter revenue guidance of $60 million to […]
Reports Fourth Quarter Revenues of $11.1 Billion; Full-Year Revenues of $42.5 Billion Posts Fourth Quarter Loss Per Share of $4.45 and Non-GAAP EPS of $1.46; Full-Year Loss Per Share of $3.99 and Non-GAAP EPS of $6.44 Completes Acquisition of MyoKardia, Expanding Leading Cardiovascular Franchise Announces Debt Tender Offer for an […]
Fourth-Quarter 2020 Worldwide Sales Were $12.5 Billion, an Increase of 5% Fourth-Quarter 2020 GAAP Loss per Share Was $0.83, Reflecting Charges Related to Acquisitions and Intangible Asset Impairments; Fourth-Quarter Non-GAAP EPS Was $1.32 Full-Year 2020 Worldwide Sales Were $48.0 Billion, an Increase of 2%; Excluding the Impact from Foreign Exchange, […]
